Literature DB >> 7297149

An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy.

J E Calvin, A A Driedger, W J Sibbald.   

Abstract

Entities:  

Mesh：

Year:  1981        PMID： 7297149     DOI： 10.1378/chest.80.5.579

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  8 in total

1.  Cardiovascular Dysfunction in Sepsis and Septic Shock.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

2.  PPARα augments heart function and cardiac fatty acid oxidation in early experimental polymicrobial sepsis.

Authors:  Stephen W Standage; Brock G Bennion; Taft O Knowles; Dolena R Ledee; Michael A Portman; John K McGuire; W Conrad Liles; Aaron K Olson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-23       Impact factor: 4.733

Review 3.  Pathophysiology of sepsis-induced cardiomyopathy.

Authors:  Steven M Hollenberg; Mervyn Singer
Journal:  Nat Rev Cardiol       Date:  2021-01-20       Impact factor: 32.419

4.  A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.

Authors:  J E Parrillo; C Burch; J H Shelhamer; M M Parker; C Natanson; W Schuette
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

5.  Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock.

Authors:  C Natanson; M P Fink; H K Ballantyne; T J MacVittie; J J Conklin; J E Parrillo
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 6.  Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis.

Authors:  Takeshi Suzuki; Yuta Suzuki; Jun Okuda; Takuya Kurazumi; Tomohiro Suhara; Tomomi Ueda; Hiromasa Nagata; Hiroshi Morisaki
Journal:  J Intensive Care       Date:  2017-03-03

7.  H2 Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression.

Authors:  Sihua Tan; Zhiyuan Long; Xiangping Hou; Yujie Lin; Jingting Xu; Xinchao You; Tinghuai Wang; Yaxing Zhang
Journal:  Front Pharmacol       Date:  2019-08-05       Impact factor: 5.810

Review 8.  Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.

Authors:  Yujiro Matsuishi; Bryan J Mathis; Nobutake Shimojo; Satoru Kawano; Yoshiaki Inoue
Journal:  Vasc Health Risk Manag       Date:  2020-04-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.